An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults

Trial Profile

An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Sodium benzoate (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors SyneuRx International (Taiwan) corp
  • Most Recent Events

    • 14 Jul 2017 According to a SyneuRx International media release, 3 subjects have been randomized from the 11 subjects screened into this trial within a short period of time.
    • 06 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 19 Mar 2017 Planned initiation date changed from 1 Jan 2015 to 29 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top